EICHORCondition: Dermatitis Atopic · Sponsor: Sanofi
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
In adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile. In these clinical trials, only patients with Eczema Area and Severity Index (EASI) score greater than or equal to (≥) 16 were enrolled, and effectiveness on sensitive/visible areas was not specifically evaluated. Further data about the effectiveness of dupilumab in adolescent participants with moderate to mild EASI score and severe itching and/or localized AD are therefore necessary to better understand the potential clinical benefits of dupilumab in these populations. This is an Italian multicenter, 52-week observational (non-interventional) study which will collect data on the characteristics of adolescent (aged 12 to 17 years) participants who suffer from severe AD with EASI score less than (\<) 16, eligible for systemic dupilumab treatment according to Italian reimbursement criteria. It will study the real-world effectiveness and safety of dupilumab in this population, the effect of dupilumab on itching (pruritus), sleep, quality of life and related outcomes, localized AD in sensitive/visible areas, and on coexisting atopic conditions in adolescent participants who receive dupilumab for AD. It will also document dupilumab treatment satisfaction and dupilumab discontinuation in the study participants.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · contact-us@sanofi.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Male or female, aged between 12 and 17 years at the baseline visit * Patients with AD who have been prescribed dupilumab according to Agenzia Italiana del Farmaco (AIFA) reimbursement criteria and fulfilling the following criteria: Patients with EASI\<16 and 1. Children's Dermatology Life Quality Index (CDLQI) ≥ 10 or 2. Peak Pruritus Numerical Rating Scale (PP-NRS) ≥ 7 or 3. localization in visible or sensitive areas (head/neck/hands or genitals) * Patients able to understand and complete study-related questionnaires * Provided signed informed consent or parental/legally acceptable representative consent and patient assent where applicable Exclusion Criteria: * Prior use of dupilumab within 6 months prior the study entry * Patients currently participating in any interventional clinical trial which modifies patient care * Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study (e.g., substance abuse) The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Investigational Site Number: 002 | Bologna, Italy | Recruiting |
| Investigational Site Number: 006 | Brescia, Italy | Recruiting |
| Investigational Site Number: 004 | Florence, Italy | Recruiting |
| Investigational Site Number: 001 | Milan, Italy | Recruiting |
| Investigational Site Number: 010 | Naples, Italy | Recruiting |
| Investigational Site Number: 011 | Naples, Italy | Recruiting |
| Investigational Site Number: 005 | Roma, Italy | Recruiting |
| Investigational Site Number: 009 | Roma, Italy | Recruiting |
| Investigational Site Number: 014 | Verona, Italy | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06192563